Heteronemin promotes iron-dependent cell death in pancreatic cancer
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-03 · 397 (3) · 1865-1874
DOI: 10.1007/s00210-023-02736-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 29.09.2023. Verfasst von Gizem Kaftan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Degree Program in Biochemistry, Graduate School of Health Sciences, Ege University, 35100, Bornova, Izmir, Turkey. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pancreatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
The marine environment has been recognized as a prolific source of potent bioactive compounds with significant anticancer properties. Among these, heteronemin, a sesterterpenoid-type natural product, has shown promise. This study delves into the potential of heteronemin as a ferroptotic agent against pancreatic cancer, using the Panc-1 cell line as a model. The cytotoxic potential of heteronemin was assessed using cell viability assays. Furthermore, its effect on lipid peroxidation was determined spectrophotometrically, while the changes it induced in autophagy- and ferritin-related protein expressions were evaluated using immunoblotting techniques. Various cell-based tests were employed to scrutinize its anticancer efficacy. Heteronemin displayed a notable cytotoxic effect, reducing cell viability by 50% at a concentration of 55 nM. This cytotoxicity was discernibly linked to ferroptosis, as evidenced by the reversal of cell death upon treatment with the ferroptosis inhibitor, ferrostatin-1. Heteronemin treatment led to a marked increase in ferroptosis markers and malondialdehyde (MDA) levels. Conversely, the expression of glutathione peroxidase-4 (GPX4), a key anti-ferroptotic protein, was suppressed. Furthermore, significant modulations in the expression of ferritinophagy- and iron-related proteins such as Atg5, Atg7, FTL, STEAP3, and DMT-1 were evident post-treatment (p < 0.05). This study underscores the potential of heteronemin as a ferroptosis inducer in pancreatic cancer cells. Given its robust cytotoxicity, heteronemin emerges as a promising lead compound for further exploration in cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral Degree Program in Biochemistry, Graduate School of Health Sciences, Ege University, 35100, Bornova, Izmir, Turkey.
- Department of Biochemistry, Faculty of Pharmacy, Afyonkarahisar Health Sciences University, 03100, Afyonkarahisar, Turkey.
- Department of Physiology, Faculty of Medicine, Izmir Katip Çelebi University, Çiğli, Izmir, Turkey.
- Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Organization of African Unity Street, Abassia, 11566, Cairo, Egypt.
- Department of Pharmaceutical Biology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, 11835, Egypt.
- Graduate Institute of Marine Biology, National Dong Hwa University, Pingtung, 944, Taiwan.
Zitieren
APA
Kaftan, G., Erdoğan, M. A., El-Shazly, M., Lu, M. C., Shih, S. P., Lin, H. Y., Saso, L., & Armagan, G. (2024). Heteronemin promotes iron-dependent cell death in pancreatic cancer. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(3), 1865-1874. https://doi.org/10.1007/s00210-023-02736-7
Vancouver
Kaftan G, Erdoğan MA, El-Shazly M, Lu MC, Shih SP, Lin HY, et al. Heteronemin promotes iron-dependent cell death in pancreatic cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(3):1865-1874. doi:10.1007/s00210-023-02736-7
BibTeX
@article{Kaftan2024,
author = {Kaftan, Gizem and Erdoğan, Mümin Alper and El-Shazly, Mohamed and Lu, Mei-Chin and Shih, Shou-Ping and Lin, Hung-Yu and Saso, Luciano and Armagan, Güliz},
title = {Heteronemin promotes iron-dependent cell death in pancreatic cancer},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
volume = {397},
number = {3},
pages = {1865--1874},
doi = {10.1007/s00210-023-02736-7}
}
EUVIMED